In January 2020, Dr. Martina Schüssler-Lenz was elected on her second mandate as the Chair of the Committee for Advanced Therapies (CAT) of the European Medicines Agency's (EMA). The CAT is the committee responsible for evaluating the quality, safety and efficacy of marketing authorisations of cell and gene therapies (Advanced Therapy Medicinal Products, ATMPs).
Since 2005 she is working as M.D. at the Paul-Ehrlich Institute in the Section Advanced Therapies and Tissue Preparations, where she has reviewed Advanced Therapies in clinical trials and marketing authorizations, and has provided advice to ATMP development and life cycle management.